Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SkinPlus-HYAL + lidocaine
- Development stage
- Unknown
- Lead developer
- Bioplus
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Intradermal, Subcutaneous
01
Overview
**SkinPlus-HYAL + lidocaine** is a combination dermal filler for aesthetic medicine, formulated with cross-linked hyaluronic acid (20mg/ml) and lidocaine (0.3%) as a local anesthetic. The hyaluronic acid component provides structural support, hydration, and volume to the skin by attracting and retaining water, thereby reducing fine lines, wrinkles, and addressing volume loss. The added lidocaine minimizes pain and discomfort during and after injection, improving patient comfort. SkinPlus-HYAL uses a multistaged cross-linking (MCL) technology, producing a highly stable and long-lasting filler that can persist for up to five years. Primary indications include facial aesthetic procedures such as correction of nasolabial folds, chin, forehead, nose, and soft tissue volumization. This is an injectable pharmaceutical product administered by trained healthcare professionals[5][1][2].
- Brand names
- SkinPlus-HYAL + lidocaine
- Other names
- SkinPlus-HYAL Implant with lidocaine
02
Targets
NaV (Voltage-gated sodium channels)CD44 (CD44 antigen)ICAM1 (Intercellular Adhesion Molecule 1)RHAMM (Hyaluronan-mediated motility receptor)
Beyond the preview
Go deeper on SkinPlus-HYAL + lidocaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SkinPlus-HYAL + lidocaine.